These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 31588803

  • 21. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An In Vitro Study.
    Tai TS, Lin PM, Wu CF, Hung SK, Huang CI, Wang CC, Su YC.
    Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
    [Abstract] [Full Text] [Related]

  • 22. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X, Hong Y, Mao Y, Chen N, Wang Q, Wang Z, Zhang L, Wang L, Shi C, Shi W, Ge H, Li A, Li X, Xia G, Liu Y.
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [Abstract] [Full Text] [Related]

  • 23. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
    Lin Z, Zhang X, Zhao F, Ru S.
    Toxicol Appl Pharmacol; 2019 Mar 01; 366():75-82. PubMed ID: 30684532
    [Abstract] [Full Text] [Related]

  • 24. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
    Elangovan S, Hsieh TC, Wu JM.
    Anticancer Res; 2008 Mar 01; 28(5A):2641-7. PubMed ID: 19035289
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G.
    Biochem Pharmacol; 2018 Jul 01; 153():230-241. PubMed ID: 29408328
    [Abstract] [Full Text] [Related]

  • 34. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
    Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI.
    Clin Cancer Res; 2016 Dec 01; 22(23):5696-5705. PubMed ID: 27542767
    [Abstract] [Full Text] [Related]

  • 35. The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells.
    Baghermanesh SS, Barati M, Hosseini A.
    PLoS One; 2024 Dec 01; 19(8):e0309289. PubMed ID: 39196911
    [Abstract] [Full Text] [Related]

  • 36. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
    McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES.
    Cell Cycle; 2012 Jul 15; 11(14):2747-55. PubMed ID: 22751436
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D, Sun X, Zhang X, Cao J.
    Biomed Res Int; 2020 Jul 15; 2020():9525207. PubMed ID: 32626773
    [Abstract] [Full Text] [Related]

  • 38. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC.
    Oncotarget; 2017 Jun 27; 8(26):42343-42358. PubMed ID: 28418845
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Cao Y, Li X, Kong S, Shang S, Qi Y.
    J Cell Mol Med; 2020 May 27; 24(9):5135-5145. PubMed ID: 32277580
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.